Ying Wang | Chromosomal Abnormalities | Best Researcher Award

Dr. Ying Wang | Chromosomal Abnormalities | Best Researcher Award 

Tongji medical college of huazhong university of science and technology | China

Author Profile

Scopus

【YING WANG: A DEDICATED HEMATOLOGY RESEARCHER】

🎓 EARLY ACADEMIC PURSUITS

Ying Wang’s passion for medicine began at a young age, inspiring her to pursue an extensive medical education. She completed eight years of rigorous training, which included five years of clinical medical study followed by three years specializing in hematology. During this time, she developed a strong interest in laboratory science and hematology technology. Her academic journey allowed her to master fundamental hematological knowledge and acquire essential experimental skills such as polymerase chain reaction (PCR), cell culture, and morphology. This foundation led her to continue her professional journey in the hematology laboratory upon graduation.

💼 PROFESSIONAL ENDEAVORS

Since 2008, Ying Wang has been working in the Hematology Laboratory of Tongji Hospital at Tongji Medical College, Huazhong University of Science and Technology. Her career began with a primary focus on cell morphology, which is the cornerstone of hematopathology. Over three years, she gained an in-depth understanding of the characteristics of different hematological testing methods, including morphology, immunology, cytogenetics, and molecular biology.

For the past seven years, her work has been centered on cytogenetics, particularly in chromosomal analysis and fluorescence in situ hybridization (FISH). Through dedicated training and hands-on practice, she has mastered G-banding chromosomal analysis and developed expertise in applying FISH techniques to malignant blood diseases.

Currently, she leads the Cytogenetics Group, overseeing four team members and ensuring the efficiency and accuracy of daily operations. Under her leadership, her team has successfully established cytogenetic analysis for blood diseases and has processed a significant volume of patient samples. Her contributions to the field are reflected in her authorship of two published research papers.

📝 CONTRIBUTIONS AND RESEARCH FOCUS ON CHROMOSOMAL ABNORMALITIES

Ying Wang’s research focuses on cytogenetic analysis in hematology, particularly in the chromosomal abnormalities associated with blood diseases. Her expertise in G-banding chromosomal analysis and FISH techniques has significantly enhanced diagnostic and prognostic capabilities in hematopathology. She has contributed extensively to the establishment and optimization of cytogenetic methodologies in her laboratory, leading to improved patient diagnoses and treatment strategies.

Despite the labor-intensive nature of cytogenetic analysis, she remains deeply passionate about her work. Knowing that her contributions provide crucial diagnostic and prognostic data to clinicians, she continues to dedicate herself to advancing the field of hematology.

🌟 IMPACT AND INFLUENCE

Ying Wang’s work has had a profound impact on the field of hematology, particularly in China. By pioneering cytogenetic analysis for blood diseases in her laboratory, she has played a critical role in improving diagnostic precision. Her leadership in the Cytogenetics Group has enabled her team to process a high volume of patient samples, ensuring timely and accurate results that guide treatment decisions.

Her research contributions have also influenced the broader scientific community through her publications. Additionally, her involvement as a member of the Hubei Medical Biology and Immunology Society demonstrates her commitment to professional collaboration and knowledge exchange within the field.

📊 ACADEMIC CITATIONS

Ying Wang has authored two peer-reviewed research papers focusing on cytogenetics and blood disease analysis. These publications have contributed to the scientific community’s understanding of chromosomal abnormalities in hematology. Her work continues to be cited by researchers working on similar topics, further solidifying her influence in the field.

💪 LEGACY AND FUTURE CONTRIBUTIONS

As she advances in her career, Ying Wang remains committed to furthering her expertise in hematology and cytogenetics. She acknowledges the limitations of her current knowledge and continuously seeks to expand her skills through further studies and international collaborations. She aspires to stay at the forefront of hematological advancements by engaging with leading laboratories worldwide.

Upon completing her further studies, she aims to implement cutting-edge techniques in her laboratory, thereby enhancing the quality and scope of cytogenetic analysis available to patients in China. Her long-term vision is to contribute to the continued evolution of hematology research and to provide even more precise and valuable diagnostic information for improved patient outcomes.

👨‍🎓 POSITIONS AND HONORS

  • 2008 – Present: Hematology Laboratory, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology (Specialized in Morphology and Cytogenetics).
  • 2017 – Present: Member, Hubei Medical Biology and Immunology Society, China.

📑NOTABLE PUBLICATIONS

"Increased Epstein‒Barr virus reactivation following prophylaxis for cytomegalovirus infection after haploidentical haematopoietic stem cell transplantation

  • Authors: X., Kong, Xin , Z., Xu, Ziyi , Y., Wu, Yanjun , Y., Zhao, Ye , F., Chen, Feng
  • Journal: Journal of Hematology and Oncology
  • Year: 2024

" Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial

  • Authors: J., Lu, Jing , H., Qiu, Huiying , Y., Wang, Ying , Y., Zhu, Yu , S., Chen, Suning
  • Journal: Journal of Hematology and Oncology
  • Year: 2024

"CD19 CAR T-cell therapy in relapsed TCF3-HLF-positive B-cell acute lymphoblastic leukemia

  • Authors: Y., Yao, Yao , J., Zhou, Jin , Y., Li, Yanting , D.P., Wu, De Pei , Y., Wang, Ying
  • Journal: Annals of Hematology
  • Year: 2024

"Risk factors for in-hospital mortality in recipients of allogeneic hematopoietic stem cell transplantation with acute respiratory distress syndrome: a retrospective study based on the 2023 new definition of acute respiratory distress syndrome

  • Authors: S., Guo, Shiqi , D., Xie, Dan , Y., Gao, Ye , Y., Wang, Ying , Q., Guo, Qiang
  • Journal: BMC Pulmonary Medicine
  • Year: 2024

"A phase II study of belumosudil for chronic graft-versus-host disease in patients who failed at least one line of systemic therapy in China

  • Authors: Y., Wang, Ying , D.P., Wu, De Pei , X., Zhang, Xiang , Y., Wang, Yu , Y., Zhang, Ying
  • Journal: BMC Medicine
  • Year: 2024

Ralph Scully | Homologous Recombination | Best Researcher Award

Dr. Ralph Scully | Homologous Recombination | Best Researcher Award

Harvard Medical School | United States

Author Profile

Scopus

Google Scholar

RALPH SCULLY: PIONEER IN GENOMIC STABILITY AND DNA REPAIR 🧬

Dr. Ralph Scully is a globally recognized leader in cancer biology, genomic stability, and DNA repair mechanisms. His illustrious academic career spans decades, marked by groundbreaking research and influential leadership in the biomedical sciences.

EARLY ACADEMIC PURSUITS 🎓

Dr. Scully began his academic journey with a B.A. (Hons) in Medical Sciences and English from the University of Cambridge in 1983, followed by an M.B., B.S. in Clinical Sciences from University College London in 1986. He later earned an M.A. in Medical Sciences and English in 1990 and culminated his academic studies with a Ph.D. in Immunology under the mentorship of Herman Waldmann, F.R.S., at Cambridge in 1994. This interdisciplinary foundation laid the groundwork for his innovative approach to medical research.

PROFESSIONAL ENDEAVORS 🏥

Dr. Scully’s professional trajectory showcases his dedication to both clinical and academic excellence:

  • Postdoctoral Training (1994-1997): Focused on neoplastic disease mechanisms at the Dana-Farber Cancer Institute under Dr. David M. Livingston.
  • Harvard Medical School Faculty: Starting as an Instructor in 1997, he progressed through the ranks to become a Professor of Medicine in 2017. He has also served as faculty for the Ph.D. Program in Biological and Biomedical Sciences.
  • Administrative Leadership: Co-Director of the Program in DNA Repair and Genomic Instability at Beth Israel Deaconess Medical Center since 2018.

CONTRIBUTIONS AND RESEARCH FOCUS ON HOMOLOGOUS RECOMBINATION🔬

Dr. Scully's research explores the molecular mechanisms of DNA repair, genomic instability, and cancer biology, particularly in relation to BRCA genes. His work has illuminated pathways critical to understanding cancer development and therapy resistance. Highlights include:

  • Leading efforts in understanding genomic rearrangements and mutational signatures in cancer.
  • Driving advancements in genome editing technologies and their implications for cancer prevention and treatment.
  • Collaborative projects on BRCA-linked cancer prevention, including international coalitions.

IMPACT AND INFLUENCE 🌍

Dr. Scully has profoundly influenced the field through:

  • Organizing major scientific conferences such as the Keystone Symposium on Genomic Instability and DNA Repair (2023) and the FASEB Conference on Genetic Recombination (2026, 2028).
  • Serving as a chair and advisory member for numerous academic committees, fostering collaborations across global institutions.
  • His mentorship of emerging scientists, equipping the next generation with critical insights into genomic medicine.

ACADEMIC CITATIONS AND RECOGNITION 📚

Dr. Scully's publications are extensively cited, reflecting the high impact of his research in genomics and cancer biology. As a thought leader, he has contributed to the editorial boards and review committees of prestigious journals and funding agencies, ensuring the dissemination of transformative research.

LEGACY AND FUTURE CONTRIBUTIONS 🌟

Dr. Scully’s ongoing commitment to tackling genomic instability has positioned him as a pioneer whose work continues to inform cancer prevention and treatment strategies. His leadership in upcoming conferences and collaborative projects signifies a lasting legacy in the biomedical field.

OTHER NOTABLE ACHIEVEMENTS 🏅

  • Professional Societies: Member of esteemed organizations such as the American Association for Cancer Research and the Association of American Physicians.
  • Consultancy Roles: Provided expert guidance to biotech companies like Editas, Cyteir, and MoMa Therapeutics.
  • Grant Reviews and Committees: Regularly contributes to panels for the NIH, ACS, and Charles A. King Trust Fellowship Program.

NOTABLE PUBLICATIONS 📑

"One-ended and two-ended breaks at nickase-broken replication forks

  • Authors: Scully, R. , Walter, J.C. , Nussenzweig, A.
  • Journal: DNA Repair
  • Year: 2024

"Exploiting CRISPR/Cas9 to engineer precise segmental deletions in mouse embryonic stem cells

  • Authors: Elango, R. , Panday, A. , Willis, N.A. , Scully, R.
  • Journal: STAR Protocols
  • Year: 2022

"A modified CUT&RUN-seq technique for qPCR analysis of chromatin-protein interactions

  • Authors: Panday, A. , Elango, R. , Willis, N.A. , Scully, R.
  • Journal: STAR Protocols
  • Year: 2022

"The structure-specific endonuclease complex SLX4–XPF regulates Tus–Ter-induced homologous recombination

  • Authors: Elango, R. , Panday, A. , Lach, F.P. , Smogorzewska, A. , Scully, R.
  • Journal: Nature Structural and Molecular Biology
  • Year: 2022

"Recombination and restart at blocked replication forks

  • Authors: Scully, R. , Elango, R. , Panday, A. , Willis, N.A.
  • Journal: Current Opinion in Genetics and Development
  • Year: 2021

Flavio Faletra | Cardiovascular Genetics and Genomics | Best Researcher Award 

Dr. Flavio Faletra | Cardiovascular Genetics and Genomics | Best Researcher Award 

University Health Authority of Central Friuli | Italy

Author Profile

Scopus
Orcid ID

Biography of Flavio Faletra: A Leader in Medical Genetics 🧬

EARLY ACADEMIC PURSUITS 🎓

Flavio Faletra began his distinguished academic journey at the University of Trieste, where he earned a Degree in Medicine and Surgery in 2005. He further specialized in Medical Genetics at the same institution, completing his specialization in 2009. Demonstrating a strong commitment to his field, Faletra pursued advanced education with a Second-level Master’s degree in Clinical Genetics from the University of Siena in 2011. His foundational academic achievements laid the groundwork for a career focused on the intersection of genetics and clinical medicine.

PROFESSIONAL ENDEAVORS 🏥

Flavio Faletra has held multiple pivotal roles in medical genetics. Since August 2023, he has been an Expert in Genetics at the Regional Health Coordination Agency (ARCS) in Friuli Venezia Giulia, Italy. Alongside his expert role, he has been a University Lecturer on contract at the University of Trieste from 2018 to 2023, contributing to the academic growth of students in the field of genetics. His professional journey includes numerous positions as a Medical Director I Level in Medical Genetics, starting with the IRCCS Burlo Garofolo (2013–2017) and progressing through roles in University Health Authority Friuli Centrale and IRCCS Burlo Garofolo until his current position, reflecting his leadership in the medical genetics field.

CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOVASCULAR GENETICS AND GENOMICS  🔬

Faletra’s research focus spans various critical areas of medical genetics, from pediatric endocrinology to rare genetic diseases. He has contributed extensively to genetic counseling and clinical genetics, with a strong emphasis on pediatric genetic disorders. His work as a Thesis Co-Surveyor and PhD Supervisor at the University of Trieste demonstrates his dedication to nurturing the next generation of geneticists. Through courses such as the Genetic Consulting in Medical Genetics Specialization School, he has shaped the landscape of medical genetics education. His involvement in pediatric endocrinology through ADE courses has brought syndromic genetic disorders to the forefront, significantly impacting the medical community’s approach to these conditions.

IMPACT AND INFLUENCE 🌍

Faletra’s influence extends beyond academia into clinical practice, where his expertise has helped shape genetic diagnostic strategies across Italy. His participation in national conferences, such as the National Congress of Human Genetics and seminars on genetic syndromes and diagnostics, marks him as a key figure in Italian medical genetics. Faletra's teaching and research efforts have particularly impacted the areas of growth retardation, fetal malformations, and syndromic genetic disorders, positioning him as a central figure in advancing genetic medicine in pediatrics.

ACADEMIC CITES 📚

Flavio Faletra's work has been cited in numerous academic publications, with topics ranging from genetic diagnostic methods to therapeutic approaches for rare genetic disorders. His research in exome sequencing and next-generation sequencing techniques has had a broad impact, being referenced widely in the fields of human genetics and pediatric medicine.

LEGACY AND FUTURE CONTRIBUTIONS 🏅

Faletra’s legacy lies in his dedication to medical genetics, particularly in the areas of pediatric syndromic diseases and clinical genetics. His contribution to education, research, and clinical practice has left an indelible mark on the field. Looking ahead, his ongoing role as an expert and lecturer promises continued contributions to genomic medicine and the advancement of personalized treatment for genetic disorders. Through his continuous involvement in research, teaching, and clinical practice, Faletra remains at the forefront of innovation in medical genetics, with the potential to further revolutionize the diagnosis and treatment of complex genetic diseases.

NOTABLE PUBLICATIONS 📑

"SRSF1 haploinsufficiency is responsible for a syndromic developmental disorder associated with intellectual disability" 

  • Authors: Bogaert, E., Garde, A., Gautier, T., Dermaut, B., Vitobello, A.
  • Journal: American Journal of Human Genetics
  • Year: 2023

"Haploinsufficiency as a Foreground Pathomechanism of Poirer-Bienvenu Syndrome and Novel Insights Underlying the Phenotypic Continuum of CSNK2B-Associated Disorders" 

  • Authors:Di Stazio, M., Zanus, C., Faletra, F., d’Adamo, A.P., Musante, L.
  • Journal: Genes
  • Year: 2023

"A new neurodevelopmental disorder linked to heterozygous variants in UNC79"

  • Authors: A., Liu, Z., Luo, S., Liao, W., & Ren, D.
  • Journal: Genetics in Medicine
  • Year: 2023

"The clinical impact of the first-trimester nuchal translucency between the 95th–99th percentiles"

  • Authors: Fantasia, I., Catagini, S., Zamagni, G., Feresin, A., & Stampalija, T.
  • Journal: Prenatal Diagnosis
  • Year: 2023

"A bird’s eye view on the use of whole exome sequencing in rare congenital ophthalmic diseases"

  • Authors: Zucco, J., Baldan, F., Allegri, L., Damante, G., Mio, C.
  • Journal: Journal of Human Genetics
  • Year: 2024